Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia

Mehic, Dino; Machacek, Jennifer; T, Schramm; Buresch, Lisbeth; Kaider, Alexandra; Eichelberger, Beate; Haslacher, Helmuth; Fillitz, Michael; Dixer, Barbara; Flasch, Tanja; Anderle, Theresa; Rath, Anja; Assinger, Alice; Ay, Cihan; Pabinger, Ingrid; Gebhart, Johanna

doi:10.1016/j.thromres.2023.01.012

Cited by 5 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung weight results supported this argument (Figure 6D,E). Additionally, P-selectin, staining in the lungs, an indicator of platelet activation, 64 showed that pDTA-Tig@CML effectively inhibited platelet activation. Furthermore, pDTA-Tig@CML demonstrated stronger inhibition of platelet activation than Tig + pDTA@CML, underscoring the benefits of a sequential rocket-mode bioactivating Tig prodrug nanoplatform.…”

Section: Biodistribution and Penetration Of Vascularmentioning

confidence: 99%

Sequential Rocket-Mode Bioactivating Ticagrelor Prodrug Nanoplatform Combining Light-Switchable Diphtherin Transgene System for Breast Cancer Metastasis Inhibition

Zou,

Sun,

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

The increased risk of breast cancer metastasis is closely linked to the effects of platelets. Our previously light-switchable diphtheria toxin A fragment (DTA) gene system, known as the LightOn system, has demonstrated significant therapeutic potential; it lacks antimetastatic capabilities. In this study, we devised an innovative system by combining cell membrane fusion liposomes (CML) loaded with the light-switchable transgene DTA (pDTA) and a ticagrelor (Tig) prodrug. This innovative system, named the sequential rocket-mode bioactivating drug delivery system (pDTA-Tig@CML), aims to achieve targeted pDTA delivery while concurrently inhibiting platelet activity through the sequential release of Tig triggered by reactive oxygen species with the tumor microenvironment. In vitro investigations have indicated that pDTA-Tig@CML, with its ability to sequentially release Tig and pDTA, effectively suppresses platelet activity, resulting in improved therapeutic outcomes and the mitigation of platelet driven metastasis in breast cancer. Furthermore, pDTA-Tig@CML exhibits enhanced tumor aggregation and successfully restrains tumor growth and metastasis. It also reduces the levels of ADP, ATP, TGF-β, and P-selectin both in vitro and in vivo, underscoring the advantages of combining the bioactivating Tig prodrug nanoplatform with the LightOn system. Consequently, pDTA-Tig@CML emerges as a promising light-switchable DTA transgene system, offering a novel bioactivating prodrug platform for breast cancer treatment.

show abstract

Section: Biodistribution and Penetration Of Vascularmentioning

confidence: 99%